Global Information
회사소개 | 문의 | 비교리스트

망막모세포종 : 파이프라인 리뷰

Retinoblastoma - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 192809
페이지 정보 영문 67 Pages
가격
US $ 2,000 ₩ 2,390,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,781,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,172,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


망막모세포종 : 파이프라인 리뷰 Retinoblastoma - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 67 Pages

망막모세포종은 망막에서 발생하는 안암입니다. 증후는 백색 동공, 눈 충혈, 시각장애, 색이 다른 홍채, 안구 종창 등입니다. 질병소인은 연령과 유전입니다. 치료법에는 화학요법, 방사선 치료, 수술 등이 있습니다.

세계 각국의 망막모세포종(Retinoblastoma) 치료법 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 각 단계 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

망막모세포종 : 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업에서 개발된 파이프라인
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Cellceutix Corp
  • Icon Bioscience Inc
  • PepVax Inc
  • Recombio SL

약제 프로파일

휴지 상태인 프로젝트

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 17.06.21

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Retinoblastoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Retinoblastoma - Pipeline by Aileron Therapeutics Inc, H1 2020
  • Retinoblastoma - Pipeline by APEIRON Biologics AG, H1 2020
  • Retinoblastoma - Pipeline by Canget BioTekpharma LLC, H1 2020
  • Retinoblastoma - Pipeline by Innovation Pharmaceuticals Inc, H1 2020
  • Retinoblastoma - Pipeline by PepVax Inc, H1 2020
  • Retinoblastoma - Pipeline by Seneca Therapeutics Inc, H1 2020
  • Retinoblastoma - Pipeline by Targeted Therapy Technologies LLC, H1 2020
  • Retinoblastoma - Pipeline by VCN Biosciences SL, H1 2020
  • Retinoblastoma - Pipeline by Y-mAbs Therapeutics Inc, H1 2020
  • Retinoblastoma - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Retinoblastoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Pipeline Review, H1 2020, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.

Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 2, 1 and 6 respectively.

Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinoblastoma - Overview
    • Retinoblastoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Retinoblastoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Retinoblastoma - Companies Involved in Therapeutics Development
    • Aileron Therapeutics Inc
    • APEIRON Biologics AG
    • Canget BioTekpharma LLC
    • Innovation Pharmaceuticals Inc
    • PepVax Inc
    • Seneca Therapeutics Inc
    • Targeted Therapy Technologies LLC
    • VCN Biosciences SL
    • Y-mAbs Therapeutics Inc
  • Retinoblastoma - Drug Profiles
    • ALRN-6924 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APN-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FL-761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FL-7729 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FL-7N1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kevetrin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omburtamab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PVX-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SVV-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • topotecan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VCN-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Retinoblastoma - Dormant Projects
  • Retinoblastoma - Product Development Milestones
    • Featured News & Press Releases
      • Jan 24, 2019: SJD Barcelona Children's Hospital is, for the first time in the world, treating a childhood cancer of the retina with the oncolytic virus VCN-01
      • Feb 29, 2016: VCN Biosciences Provides Update on its lead candidate VCN-01
      • Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
      • Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
      • Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma
      • Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma
      • Oct 31, 2012: VCN Biosciences at the 2012 Annual Meeting of the European Society of Cell & Gene Therapy in Versailles
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q